Peer Review Committee for Leukemia, Immunology, and Blood Cell Development (LIB)

Areas Reviewed

Basic, preclinical, and clinical applications involving aspects of immunologic therapies of
cancer and modulation of immune responses to cancer including:

  • active and passive immune therapies for cancer
  • adoptive transfer of autologous or allogeneic hematopoietic cells
  • targeted delivery of toxic payloads
  • immune tolerance
  • hematologic malignancies  including leukemia and lymphoma
  • hematopoiesis
  • molecular, structural, biochemical and biophysical aspects of the immune system including cell types, cytokines, antigen processing, antibody molecules, and deficiencies

Committee Members

Jose Guevara-Patino, MD, PhD, Chair
Loyola University, Chicago
Maywood, IL

Zhenglun (Jerry) Zhu, MD, PhD, Co-Chair
Brigham and Women’s Hospital
Boston, MA

Ricky Bolick, Stakeholder
Granite Falls, NC

Jianjun Chen, PhD
University of Cincinnati
Cincinnati, OH

Stephen Gottschalk, MD
Baylor College of Medicine
Houston, TX

Michael Gough, PhD
Providence Portland Medical Center
Portland, OR

Sergei Grivennikov, PhD
Fox Chase Cancer Center
Philadelphia, PA  19111

Karen Haas, PhD
Wake Forest University
Winston Salem, NC

Sharon Likely, Stakeholder
Clements, CA

Natarajan Muthusamy, DVM, PhD
Ohio State University
Columbus, OH

Guangyong Peng, MD, PhD
Saint Louis University
Saint Louis, MO

Neha Reddy Pidatala, Stakeholder
New York, NY

Iryna Pinchuk, PhD
University of Texas Medical Branch, Galveston
Galveston, TX 

Christopher Porter, MD
Emory University
Atlanta, GA

Zhijian Qian, PhD
University of Florida
Gainesville, FL

Mark Rubinstein, PhD
University of South Carolina
Charleston, SC

Deepa Sampath, PhD
Ohio State University
Columbus, SC

Sandra Zinkel, MD, PhD
Vanderbilt University
Nashville, TN